Pancreatic cancer - Is the wall crumbling?

Annals of Oncology

Volumn 19, Issue 7, 2008, Pages 1224-1230

  Chua, Y J ^a   Zalcberg, J R ^b,c  

^a CANBERRA HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Adenocarcinoma; Advanced; Chemotherapy; Gemcitabine; Metastatic; Pancreas

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLIC ACID ANTAGONIST; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MARIMASTAT; OXALIPLATIN; PEMETREXED; PLACEBO; PLATINUM DERIVATIVE; RUBITECAN; TANOMASTAT; TIPIFARNIB;

ADVANCED CANCER; BONE MARROW SUPPRESSION; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG METABOLISM; DRUG RESPONSE; FLU LIKE SYNDROME; HUMAN; LETHARGY; METASTASIS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 46249092188     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn063     Document Type: Review

References (51)

1. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2): 74-108.
2. Glimelius B, Hoffman K, Sjoden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7(6): 593-600.
3. Palmer KR, Kerr M, Knowles G et al, Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994; 81(6): 882-885.
4. Mallinson CN, Rake MO, Cocking JB et al. Chemotherapy in pancreatic cancer: Results of a controlled, prospective, randomised, multicentre-trial. BMJ 1980; 281(6255): 1589-1591.
5. Burris HA III, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15(6): 2403-2413.
6. Hochster HS, Newer approaches to gemcitabine-based therapy of pancreatic cancer: Fixed-dose-rate infusion and novel agents. Int J Radiat Oncol Biol Phys 2003; 56 (4 Suppl): 24-30.
7. Touroutoglou N, Gravel D, Raber MN et al. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 1998; 90; 1003-1008.
8. Tempero M, Plunkett W, Ruiz Van Haperen V et al. Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003; 21(18): 3402-3408.
9. Poplin E, Levy DE, Berlin J et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol 2006; 24 (18 Suppl): (Abstr LBA4004).
10. Cunningham D, Chau I, Stocken D et al. Phase III randomised comparison of gemcitabine (GEM) with gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer Suppl 2005; 3(2): 12.
11. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25(15): 1960-1966.
12. Milano G, Ferrero JM, Francois E. Comparative pharmacology of oral fluoropyrimidines: A focus on pharmacokinetics, pharmacodynamics and pharmacomodulation. Br J Cancer 2004; 91(4): 613-617.
13. Cartwright TH, Cohn A, Varkey JA et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002; 20(1): 160-164.
14. Herrmann R, Bodoky G, Ruhstaller T et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007; 25(16): 2212-2217.
15. Berlin JD, Catalano P, Thomas JP et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20(15): 3270-3275.
16. Riess H, Helm A, Niedergethmann M et al. A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol 2005; 23 (16S Suppl): 310s (Abstr LBA4009).
17. Wils JA, Kok T, Wagener DJ et al. Activity of cisplatin in adenocarcinoma of the pancreas. Eur J Cancer 1993; 29A(2): 203-204.
18. Brodowicz T, Wolfram RM, Kostler WJ et al. Phase 11 study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer, Anticancer Drugs 2000; 11(8): 623-628.
19. Heinemann V, Wilke H, Mergenthaler HG et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000; 11(11): 1399-1403.
20. Philip PA, Zalupski MM, Vaitkevicius VK et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 2001; 92(3): 569-577.
21. Cascinu S, Labianca R, Catalano V et al. Weekly gemcitabine and cisplatin chemotherapy: A well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol 2003; 14(2): 205-208.
22. Heinemann V, Quietzsch D, Gieseler F et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24(24): 3946-3952.
23. Colucci G, Giuliani F, Gebbia V et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized phase III study of the Gruppo Oncologia dell'Italla Meridionale. Cancer 2002; 94(4): 902-910.
24. Alberts SR, Townley PM, Goldberg RM et al. Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: A North Central Cancer Treatment Group phase II study. Ann Oncol 2003; 14(4): 580-585.
25. Louvet C, Andre T, Lledo G et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: Final results of a GERCOR multicenter phase II study. J Clin Oncol 2002; 20(6): 1512-1518.
26. Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23(15): 3509-3516.
27. Heinemann V, Labianca R, Hinke A et al. Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: Pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol 2007; 18(10): 1652-1659.
28. Yip D, Karapetis C, Strickland A et al. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 2006; 3: (CD002093).
29. O'Reilly EM, Abou-Alfa GK, Letourneau R et al. A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs, gemcitabine alone in advanced pancreatic cancer (APC). J Clin Oncol 2004; 23 (14S Suppl): (Abstr LBA4006).
30. Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22(18): 3776-3783.
31. Oettle H, Richards D, Ramanathan RK et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patents with unresectable or metastatic pancreatic cancer. Ann Oncol 2005; 16(10): 1639-45.
32. Stathopoulos GP, Mavroudis D, Tsavaris IN et al. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony stimulating factor: A phase II study of the Greek Cooperative Group for Pancreatic Cancer Ann Oncol 2001; 12(1): 101-103.
33. Ryan DP, Kulke MH, Fuchs CS et al. A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 2002; 94(1): 97-103.
34. Shepard RC, Levy DE, Berlin JD et al. Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the Eastern Cooperative Oncology Group. Oncology 2004; 66(4): 303-309.
35. Philip PA, Benedetti J. Fenoglio-Preiser C et al. Phase III study of gemcitabine, [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. ASCO Meeting Abstracts 2007; 25 (18 Suppl): (Abstr LBA4509).
36. indler HL, Niedzwiecki D, Hollis D et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB). ASCO Meeting Abstracts 2007; 25 (18 Suppl): (Abstr 4508).
37. Cohen SJ, Ho L, Ranganathan S et al. Phase II and pharmacodynamic study of the famesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 2003; 21(7): 1301-1306.
38. Van Cutsem E, van de Velde H, Karasek P et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22(8): 1430-1438.
39. Evans JD, Stark A, Johnson CD et al. A phase II trial of marimastat in advanced pancreatic cancer. Br J Cancer 2001; 85(12): 1865-1870.
40. Bramhall SR, Rosemurgy A, Browh PD et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial. J Clin Oncol 2001; 19(15): 3447-3455.
41. Bramhall SR, Schulz J, Nemunaitis J et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat: With gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87(2): 161-167.
42. Moore MJ, Hamm J, Dancey J et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21(17): 3296-3302.
43. Oettle H, Pelzer U, Stieler J et al. Oxaliplatin/folinic acid/ 5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). J Clin Oncol 2005; 23 (16S Suppl): 315s (Abstr 4031).
44. Van Laethem JL, Polus M, Marechal R et al. Gemcitabine and oxaliplatine (GEMO)Q in gemcitabine-refractory advanced pancreatic cancer a phase II study. J Clin Oncol 2004; 23 (14S Suppl): 342 (Abstr 4119).
45. Chauffert B, Mornex F, Bonnetain F et al. Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study. ASCO Meeting Abstracts 2006; 24 (18 Suppl): (Abstr 4008).
46. Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988; 80(10): 751-755.
47. Hazel JJ, Thirlwell MP, Huggins M et al. Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: A prospective randomized trial. J Can Assoc Radiol 1981; 32(3): 164-165.
48. Klaassen DJ, MacIntyre JM, Catton GE et al. Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - an Eastern Cooperative Oncology Group study. J Clin Oncol 1985; 3(3): 373-378.
49. Sultana A, Tudur Smith C, Cunningham D et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 2007; 96(8): 1183-1190.
50. Van Cutsem E, Verslype C, Grusenmeyer PA. Lessons learned in the management of advanced pancreatic cancer. J Clin Oncol 2007; 25(15): 1949-1952.
51. Hochster HS, Haller DG, de Gramont A et al. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer 2006; 107(4): 676-685.